Tesamorelin VAT Reduction Protocol

The evidence base in plain English

Tesamorelin is a synthetic analog of GHRH (growth hormone releasing hormone, the hormone that tells the pituitary to release growth hormone). Unlike CJC-1295 and similar GHRH analogs, tesamorelin made it through full FDA phase-3 trials and earned approval in 2010.

The landmark Falutz NEJM 2007 trial randomized 412 HIV patients with abdominal fat accumulation to 2mg subcutaneous tesamorelin daily or placebo for 26 weeks. The drug-treated group lost 15.4% of visceral adipose tissue versus a 2% gain in placebo (P<0.001), with no significant change in subcutaneous fat - meaning the effect was specifically on visceral fat, not on body weight broadly (Falutz et al. 2007, NEJM; PMID 18057338).

The Stanley JAMA 2014 trial extended this work, showing tesamorelin produced -15.4% VAT versus +5% in placebo at week 26 in HIV patients with abdominal fat accumulation, with associated improvements in liver fat (Stanley et al. 2014, JAMA; PMID 25038357).

A pooled analysis of two phase-3 trials confirmed the visceral-fat-specific effect across a larger population (PMID 20554713 - Falutz et al. 2010, JAIDS). Tesamorelin reduces visceral fat by 15 to 18% over 26 weeks across studies, while leaving subcutaneous fat largely unchanged.

The off-label HIV-negative evidence is thinner. Some clinical work has examined tesamorelin in non-HIV NAFLD/NASH (non-alcoholic fatty liver disease) populations and shown liver fat reduction, but the visceral-fat data outside HIV-associated lipodystrophy is mostly inferred from the HIV trials and from clinic practice.

Honest framing: this is the strongest VAT-specific molecule in the peptide adjacent space. It is also expensive, requires daily injection for 26 weeks, and has a side-effect profile that needs monitoring.

Week 0: the doctor conversation

The right starting point is a metabolic-medicine doctor, an endocrinologist, or a longevity-clinic provider with experience prescribing tesamorelin off-label for general VAT reduction. A general practitioner is unlikely to write this script.

Three questions for the appointment:

• Is my VAT level documented? Tesamorelin is the right tool when VAT is documented as elevated on imaging - typically a CT scan or MRI cross-section showing visceral fat area, or a DEXA scan showing trunk fat distribution. Without a baseline VAT measurement, you cannot tell if the protocol is working at week 26.
• Branded Egrifta or compounded tesamorelin? Branded Egrifta (manufactured by Theratechnologies) is the FDA-approved path. Cost is high - typically $3,000 to $5,000 per month at retail without insurance, with manufacturer copay programs bringing it down for HIV patients with the on-label indication. Compounded tesamorelin from a peptide-experienced compounding pharmacy is the more common path for off-label HIV-negative use, at a lower cost ($200 to $500 per month). Your provider should explain which path their script will use and what the cost path looks like.
• What is the monitoring plan? Standard pre-protocol bloodwork includes IGF-1 (a downstream growth hormone marker), fasting glucose, HbA1c (a 3-month average blood sugar measure), lipid panel, and liver enzymes. Plan to repeat the panel at weeks 12 and 26 to track glucose tolerance and IGF-1 levels.

If your provider says "tesamorelin for general VAT in an HIV-negative adult is off-label and I am not comfortable prescribing it," that is a defensible position. Find a longevity-clinic second opinion if the protocol is right for your case.

Week 1: sourcing

The legitimate paths in 2026:

• Branded Egrifta or Egrifta WR (Theratechnologies). The original Egrifta requires daily reconstitution from a powder; Egrifta WR is a more concentrated, once-daily formulation approved for the same indication. Brand-name path with the pharmaceutical-grade quality control and the FDA label behind it. Expensive, but legitimate.
• Compounded tesamorelin from a 503A or 503B compounding pharmacy via a peptide-experienced telehealth or longevity-clinic provider. Cheaper than branded but legality and quality vary by pharmacy. Ask for the COA per batch.
• Skip: Research peptide vendors selling "tesamorelin" without a prescription. Tesamorelin is on the FDA's radar specifically because of off-label use; the research-vendor space here is murkier than the wider peptide market. The dose precision and identity verification are not what you want to compromise on for a 26-week daily-injection protocol.
• Skip: "Tesamorelin pills" or oral formulations. The molecule is a peptide that requires subcutaneous injection. There is no legitimate oral version.

Storage: refrigerated at 36 to 46 degrees F. Reconstitute fresh per pharmacy instructions. Discard any vial that has been at room temperature for longer than the manufacturer's stated stability window.

Weeks 2-27: the 26-week cycle

The protocol that produced the Falutz NEJM 2007 and Stanley JAMA 2014 results:

• 2mg tesamorelin subQ once daily, typically at bedtime to align with the natural overnight GH pulse, for 26 consecutive weeks (Egrifta Prescribing Information, 2025).
• Inject in rotating abdominal sites. The abdomen is the primary injection site per the FDA label. Rotate sites to avoid lipodystrophy at any single injection point.
• Pair with a stable diet and training routine. The protocol is studied alongside normal lifestyle, not alongside an aggressive cut. Adding a major caloric deficit on top of tesamorelin makes attribution impossible at the week-26 readout.
• Monitor at week 12. Repeat fasting glucose, HbA1c, IGF-1, and liver enzymes at the midpoint. If glucose tolerance has worsened materially, your provider may pause or dose-reduce. IGF-1 substantially above the age-matched reference range is also a stop signal.
• Reassess VAT at week 26. Repeat the imaging or DEXA you used at baseline. If VAT has dropped 15 to 20% as the trials predicted, the protocol worked. If it has not, continuing past 26 weeks is not supported by the evidence.
• Plan the off-period. The trial protocols ran 26 weeks on. Some patients run a maintenance dose afterward (1 to 2mg daily for an additional 26 weeks); others cycle off entirely. Discuss with your provider before week 26.

What success looks like

The realistic outcomes from a 26-week cycle:

• Week 4 to 8: waist circumference may begin to drop measurably. Changes in scale weight may be small or absent because the visceral fat reduction is offset by lean tissue gain from the GH-axis effect.
• Week 12: repeat bloodwork should show stable or slightly elevated IGF-1, stable to modestly improved liver enzymes and lipid markers in many users. Glucose tolerance should be stable - if it has worsened materially, that is a stop signal.
• Week 26: repeat imaging should show a 15 to 20% reduction in VAT cross-sectional area, consistent with the Falutz and Stanley trial results. Subcutaneous fat will likely be largely unchanged.
• What does not happen: dramatic scale-weight change. Tesamorelin is a body-recomposition tool more than a weight-loss tool. The protein- and lean-tissue-supporting GH-axis effect can offset visceral fat loss on the scale.

If the week-26 imaging shows no change in VAT, the protocol did not work for you and continuing is not supported by the evidence base. Stop and have the conversation about what other tool fits your case.

What to skip

• Stacking tesamorelin with exogenous HGH. The whole point of the GHRH-analog approach is that it lets your own pituitary control the dosing rhythm. Adding exogenous HGH suppresses your own pituitary signaling. The two work against each other.
• "Tesamorelin + Ipamorelin combo blends" in a single vial from research vendors. Stacking a long-acting GHRH analog with a GH secretagogue has no published clinical basis at the doses sold in this space, and the safety question (combined IGF-1 elevation and downstream signaling) is not addressed in any RCT.
• Continuous use beyond 52 weeks without imaging-based justification. The trial evidence is on 26-week and (in extension data) 52-week windows. Indefinite use is not what was studied.
• Tesamorelin in patients with active diabetic retinopathy or active malignancy. Both are listed contraindications on the FDA label and the off-label use cases do not change that.

Subscribe to the dispatch

The weekly Protocol One dispatch covers what's moving in peptides, GLP-1s, and longevity protocols. Broken down for normal humans.

Subscribe free